What is Eli Lilly's revenue?

Eli Lilly (LLY) generated $72.2B in revenue over the trailing twelve months, up 47.4% year over year.

Is Eli Lilly profitable?

Eli Lilly reported $25.3B in net income over the trailing twelve months, a 35.0% net margin.

What is Eli Lilly's earnings per share?

Eli Lilly's diluted EPS over the trailing twelve months is $28.15.

Where does Eli Lilly's income statement data come from?

Every line is extracted from Eli Lilly's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Eli Lilly LLY Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Total revenue	$19.8B+2.6%	$19.29B+9.6%	$17.6B+13.1%	$15.56B+22.2%	$12.73B-5.9%
Total cost of revenue	$3.58B+6.1%	$3.37B+12.1%	$3.01B+22.9%	$2.45B+10.0%	$2.23B-7.4%
Gross profit	$16.22B+1.9%	$15.92B+9.1%	$14.59B+11.3%	$13.11B+24.8%	$10.5B-5.6%
Gross margin	81.9%-0.6pp	82.5%-0.4pp	82.9%-1.4pp	84.3%+1.7pp	82.5%+0.3pp
Research and development	$3.51B-7.7%	$3.8B+9.7%	$3.47B+3.9%	$3.34B+22.0%	$2.73B-9.6%
Selling, general and administrative	$2.93B-6.3%	$3.13B+14.3%	$2.74B-0.4%	$2.75B+11.5%	$2.47B+1.8%
Other income (expense), net	-$65M+40.0%	-$108.3M+18.6%	-$133.1M-46.9%	-$90.6M+62.1%	-$239M-116%
Income before income taxes	$8.85B+7.1%	$8.27B+14.3%	$7.23B+6.7%	$6.78B+96.1%	$3.46B-31.4%
Income tax expense	$1.45B-10.7%	$1.63B-1.3%	$1.65B+47.9%	$1.12B+60.1%	$697M+10.9%
Net income	$7.4B+11.4%	$6.64B+18.9%	$5.58B-1.4%	$5.66B+105%	$2.76B-37.4%
Net margin	37.4%+2.9pp	34.4%+2.7pp	31.7%-4.7pp	36.4%+14.7pp	21.7%-10.9pp
Diluted earnings per share	$8.26+11.8%	$7.39+19.0%	$6.21-1.3%	$6.29+106%	$3.06-37.3%
Basic earnings per share	$8.27+11.8%	$7.40+19.0%	$6.22-1.3%	$6.30+105%	$3.07-37.3%
Weighted-average shares, diluted	895.9M-0.4%	899.3M+0.1%	898.8M-0.1%	899.8M-0.1%	900.6M-0.4%
Weighted-average shares, basic	894.5M-0.3%	897.3M0.0%	896.9M-0.1%	897.9M-0.1%	898.7M-0.2%
Acquired in-process research and development	$584M+10.4%	$528.8M-19.4%	$655.7M+326%	$153.8M-90.2%	$1.57B+733%
Cost of sales, operating expenses, and other-net	$10.95B-0.7%	$11.03B+6.3%	$10.37B+18.1%	$8.78B-5.3%	$9.27B+9.2%
Impairment and restructuring	$279M+232%	$84.1M-77.0%	$364.9M—	$0-100%	$35M-89.8%
Cost Of Sales, Operating Expenses, And Other-net	$10.95B-0.7%	$11.03B+6.3%	$10.37B+18.1%	$8.78B-5.3%	$9.27B+9.2%
Research and development expense	$3.51B-7.7%	$3.8B+9.7%	$3.47B+3.9%	$3.34B+22.0%	$2.73B-9.6%
EBIT	$8.85B+7.1%	$8.27B+14.3%	$7.23B+6.7%	$6.78B+96.1%	$3.46B-31.4%
EBITDA	$9.36B+5.7%	$8.85B+14.9%	$7.7B+6.2%	$7.25B+85.1%	$3.92B-29.0%
EBITDA	$9.36B+5.7%	$8.85B+14.9%	$7.7B+6.2%	$7.25B+85.1%	$3.92B-29.0%
EBITDA margin	47.3%+1.4pp	45.9%+2.1pp	43.8%-2.9pp	46.6%+15.8pp	30.8%-10.0pp
EBIT	$8.85B+7.1%	$8.27B+14.3%	$7.23B+6.7%	$6.78B+96.1%	$3.46B-31.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Eli Lilly.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Eli Lilly's revenue?: Eli Lilly (LLY) generated $72.2B in revenue over the trailing twelve months, up 47.4% year over year.
Is Eli Lilly profitable?: Eli Lilly reported $25.3B in net income over the trailing twelve months, a 35.0% net margin.
What is Eli Lilly's earnings per share?: Eli Lilly's diluted EPS over the trailing twelve months is $28.15.
Where does Eli Lilly's income statement data come from?: Every line is extracted from Eli Lilly's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.